IP Library Granted Patent US 7,547,683
Granted Patent B2
US 7,547,683 · App. 11/539,900 · Granted Jun 16, 2009

Nucleic acid injected into hepatic vein lumen

Assignee: Roche Madison, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,547,683
App. No.
11/539,900
Granted
Jun 16, 2009
Kind
B2
Abstract

Processes are described for obtaining high levels of gene expression in primates after injection of nucleic acid to the liver via the lumen of the hepatic vein. The described process results in high level of gene expression with transient increases in liver enzymes.

Claims (23)

1. A process for delivering a polynucleotide to a liver cell in a mammal, comprising:

a) forming an occlusion in a hepatic vessel in said mammal; and,

b) injecting the polynucleotide in a solution into the lumen of said hepatic vessel.

2. The process of claim 1 wherein the hepatic vessel consists of a hepatic vein.

3. The process of claim 1 wherein the hepatic vessel consists of a hepatic artery.

4. The process of claim 1 wherein the hepatic vessel consists of a portal vein.

5. The process of claim 1 wherein the hepatic vessel consists of a bile duct.

6. The process of claim 1 further comprising occluding a hepatic vein.

7. The process of claim 1 further comprising forming occlusions in one or more efferent or afferent hepatic blood vessels.

8. The process of claim 1 further comprising suppressing the immune system of said mammal.

9. The process of claim 1 wherein the solution is injected at a rate of 18 ml/kg/min or greater.

10. The process of claim 1 wherein the solution is injected at a rate of 36 ml/kg/min or greater.

11. The process of claim 1 wherein the solution is injected at a rate of 48 ml/kg/min or greater.

12. The process of claim 1 wherein the injection of the solution results in vessel pressure of 10 mm Hg or greater.

13. The process of claim 1 wherein the injection of the solution results in vessel pressure of 45 mm Hg or greater.

14. The process of claim 1 wherein the injection of the solution results in vessel pressure of 105 mm Hg or greater.

15. The process of claim 1 wherein the polynucleotide is selected from the group consisting of naked DNA, viral vector and non-viral vector.

16. The process of claim 1 wherein the polynucleotide is selected from the group consisting of blocking polynucleotide, antisense nucleic acid, siRNA, plasmid, and expression vector.

17. A process for delivering a polynucleotide to a liver cell in a mammal, comprising:

a) forming an occlusion in a hepatic vessel in said mammal;

b) injecting the polynucleotide in a solution into the lumen of said hepatic vessel;

c) removing said occlusion; and,

d) repeating the injection procedure of steps a, b, and c one or more times.

Assignments (3)
CHANGE OF NAME Recorded Feb 26, 2014
From: ROCHE MADISON INC.
To: ARROWHEAD MADISON INC.
Reel/Frame 032302/0843 →
CHANGE OF NAME Recorded Aug 10, 2009
From: MIRUS BIO CORPORATION
To: ROCHE MADISON INC.
Reel/Frame 023081/0128 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2008
From: BUDKER, TATYANA; WOLFF, JON A; HAGSTROM, JAMES E; HEGGE, JULIA
To: MIRUS BIO CORPORATION
Reel/Frame 021454/0530 →
Continuity (7)
Continuation 1031039800 · Dec 5, 2002
Continuation In Part 0944796600 · Nov 23, 1999
Continuation In Part 0939126000 · Sep 7, 1999
Division 0897557300 · Nov 21, 1997
Continuation 0857153600 · Dec 13, 1995
Provisional Application 6033798600 · Dec 5, 2001
Related Publication 20070105804A1 · May 10, 2007